Advertisment

New Horizons in Neurofibromatosis Treatment: Navigating Recent Advances and Future Prospects

author-image
Dr. Jessica Nelson
New Update
NULL

New Horizons in Neurofibromatosis Treatment: Navigating Recent Advances and Future Prospects

Advertisment

A Turning Point in Neurofibromatosis Treatment

Advertisment

Neurofibromatosis (NF), a genetic condition causing tumors to grow on nerve tissues, has witnessed a significant breakthrough with the approval of the first medical treatment for it. With the introduction of the MEK inhibitor Selumetinib (Koselugo) in 2020, the landscape of NF treatment has seen a positive shift. Notably, NF1, the most common type of neurofibromatosis, is caused by a mutation in the NF1 gene on chromosome 17. This advancement marks a turning point in NF treatment, offering new hope to patients.

Accelerating Research and Development in NF Treatment

Selumetinib's approval has led to an acceleration in research and development in the field of NF treatment. About ten companies are currently working on novel NF treatments, with 67 studies currently in progress. Promising results have been announced for a novel topical MEK inhibitor, NFX‑179 gel, for the treatment of cutaneous neurofibromas in people with NF1. This treatment has shown potential in reducing cutaneous neurofibromas, with a safety advantage over systemic treatment. Several other MEK inhibitors are also being tested in various stages of clinical trials for NF.

Advertisment

Koselugo: A New Hope for Pediatric NF1 Patients

Another significant development is the availability of Koselugo (selumetinib) in Malaysia for pediatric patients with NF1 who have symptomatic, inoperable plexiform neurofibromas. The regulatory approval of Koselugo and the results of a pivotal SPRINT trial, which showed a confirmed partial response rate of 70% with this drug, symbolizes a potential transformation in the lives of individuals suffering from NF1. This development can reduce the high unmet medical need of NF1 patients and aims to transform the lives of people affected by rare diseases in Malaysia through the development and delivery of innovative medicines.

Combating Malignant Peripheral Nerve Sheath Tumors

Advertisment

Recent studies led by investigators at the Johns Hopkins Kimmel Cancer Center and Johns Hopkins Drug Discovery have shown promising results for treating malignant peripheral nerve sheath tumors. By combining experimental drugs that block the metabolism of glutamine and purines, the size of peripheral nerve sheath tumors in mice can be reduced, and survival rates can be increased. This combination has proven to be less toxic than previously tested drug combinations, offering a potential new avenue for treatment.

New Insights into NF1 Tumor Microenvironment

Recent research has shed light on the distinctive mesenchymal-like neurofibroma stem cells (MNSCs) in NF1 patients. It has been revealed that NF1 contains a new subgroup of MNSCs with self-renewal, multiple differentiation, and tumorigenic capabilities. Furthermore, brain-derived neurotrophic factor (BDNF) can modulate these MNSCs and control different tumor phenotypes between the head and trunk regions. This discovery opens the door to potential new strategies for managing NF1, including the systemic administration of BDNF neutralizing antibodies.

Conclusion

The future looks promising for finding better answers and making progress in the treatment of NF. With continuous research and development, and the introduction of new treatment methods, there is newfound hope for individuals suffering from neurofibromatosis. The advancements in the understanding of the disease's biology, development of targeted therapies, and enhancement of existing treatment methods are paving the way for more effective and less toxic therapeutic options for NF patients.

Advertisment
Chat with Dr. Medriva !